Celldex Therapeutics Inc. (CLDX) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Celldex Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances
Price
$29.66
−1.63% today
Market cap
$2.4B
Overall quality
38/100
Kronos AI 30-day
+10.1%
8 of 8 simulated paths end higher
Celldex Therapeutics Inc. (CLDX) is a Health Care company in Biotechnology: In Vitro & In Vivo Diagnostic Substances, worth $2.4B. It trades at $29.66, down 1.63% today. Its overall quality score is 38 out of 100, ranked against the whole US market. 11 analysts' average target of $66.17 implies +123.1% from today's price. Kronos AI's 30-day forecast is +10.1% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $66.17 |
| Low – high | $28.00 – $100.00 |
| Analysts | 11 |
| Upside to average | +123.1% |
Kronos AI 30-day forecast
| Expected close | $33.18 (+10.1%) |
| Likely range | +3.0% … +13.7% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 41 |
| Solvency | 57 |
| Growth | 15 |
| Overall | 38 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: In Vitro & In Vivo Diagnostic Substances
For information only, not investment advice. Prices updated: 2026-10-29.